Figure 1.

Pharmacological inhibition of P2RY6 attenuates inflammatory features of LPS-induced ARDS during prophylactic treatment. (A) Schematic representation of the prophylactic treatment protocol. Wild-type female mice received i.t. administration of MRS2578 or PBS, followed 30 minutes later by i.t. administration of LPS or PBS. Mice were euthanized 24 hours after LPS challenge. (B, C) Estimated numbers of Ly6G+F4/80⁻ neutrophils and F4/80+Ly6G⁻ macrophages in BAL fluid, expressed as cells per mouse, were quantified by flow cytometry following prophylactic P2RY6 inhibition. Data are presented as estimated cell numbers per mouse. n indicates the number of mice analyzed. (D–H) Concentrations of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and chemokines (MIP-2 and KC) in BAL were measured following prophylactic treatment using an R&D Systems. (I) Pulmonary vascular leakage was assessed by Evans blue–albumin extravasation. Evans blue dye (20 mg/kg) was intravenously injected via the tail vein and dye accumulation in lung tissue was quantified spectrophotometrically. Data are presented as mean ± SEM. Statistical analysis was performed using ordinary one-way ANOVA followed by Šídák’s multiple-comparisons test, comparing each treatment group with the LPS control group (PBS/LPS). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.